Key clinical point: A majority of bimekizumab-treated patients in both studies achieved total skin clearance at week 16 and maintained their response for a year.

Major finding: In BE VIVID, 85% of patients in the bimekizumab arm achieved a Psoriasis Area and Severity Index score of 90 at week 16, while 81.6% achieved PASI 90 at week 52. In BE READY, the proportion of patients on bimekizumab who achieved a PASI 90 at week 56 ranged from 86.8% to 90%.

Study details: Two phase 3 randomized, double-blinded, placebo-controlled trials.

Disclosures: Both studies were funded by UCB Pharma. Dr. Reich disclosed that he has served as adviser and/or paid speaker for and/or participated in clinical trials sponsored by companies that include UCB . Dr. Gordon disclosed that he has received honoraria and/or research support from companies that include UCB.